Archive · 24 Jun 2025
Favipiravir Shows Promise in Preclinical Trials Against Chandipura Virus
Scientists are testing a drug called Favipiravir to fight a virus called Chandipura, which causes fever and seizures.
In studies on mice, the drug helped them get better.
The virus is common in central India, and there was a big outbreak recently.
Researchers hope this drug could help people, but they need to do more tests to make sure it's safe and works well for humans.
They are also working on creating a vaccine to prevent the disease.
Favipiravir shows promise against the Chandipura virus in preclinical studies.
Studies on mice showed Favipiravir reduced viral load and improved survival rates.
The Chandipura virus (CHPV) is endemic in central India, causing fever and seizures.
A major outbreak occurred in Gujarat and surrounding areas, the largest in 20 years.
Clinical trials on humans are yet to be carried out to confirm its efficacy and safety.
- Who
- Researchers at the National Institute of Virology (NIV) are studying the drug.
- What
- Favipiravir shows promise against the Chandipura virus.
- When
- The study was conducted recently and the major outbreak was reported in 2024.
- Where
- The Chandipura virus is endemic in central India.
- Why
- To find a treatment for the Chandipura virus.
Researchers' Perspective
N/A
Drug Efficacy
Researchers' Perspective
Favipiravir shows substantial protection against the virus in lab studies.
N/A
N/A
Human Trials
Researchers' Perspective
More research and testing are needed to prove efficacy.
N/A
N/A
- Drug
- Favipiravir
- Virus
- Chandipura (CHPV)
- Symptoms
- Fever, seizures, encephalitis
- Location of outbreak
- Gujarat and surrounding areas of Maharashtra
- Study type
- Preclinical
- Transmission
- Arthropod vectors, likely sand flies